Treatment Approach for Secondary HLH due to EBV Infection

Initial Assessment and Treatment Strategy

The American Society of Hematology recommends a treatment approach that includes a combination of corticosteroids, rituximab, and etoposide for rapidly deteriorating patients with secondary Hemophagocytic Lymphohistiocytosis (HLH) due to Epstein-Barr Virus (EBV) infection, with consideration for hematopoietic stem cell transplantation in refractory cases 1
For rapidly deteriorating patients, immediate intervention with etoposide-containing regimens is necessary, as recommended by the American Society of Hematology 1
Initial therapy for EBV-HLH typically includes corticosteroids, such as prednisolone 1-2 mg/kg or dexamethasone 5-10 mg/m², to suppress inflammatory cytokine production, as suggested by the American College of Physicians 1
Intravenous Immunoglobulin (IVIG) at 1.6 g/kg over 2-3 days may be used for its anti-inflammatory effects in patients with EBV-HLH, as recommended by the Infectious Diseases Society of America 1

Rituximab, at a dose of 375 mg/m² once weekly for 2-4 times, should be added to HLH-directed therapy to clear the viral reservoir in patients with EBV-HLH, as recommended by the American Society of Hematology 1
Monitoring of ferritin, soluble CD25, cell counts, and EBV DNA levels should guide the number of rituximab doses needed, as suggested by the American College of Physicians 1

For severe or deteriorating cases, the HLH-94 protocol should be initiated, which includes etoposide and dexamethasone, as recommended by the American Society of Hematology 1
Etoposide is highly effective against T-cell proliferation and cytokine secretion in patients with EBV-HLH, as suggested by the American College of Physicians 1

For patients with continuously increasing or sustained high levels of EBV DNA, hematopoietic stem cell transplantation (HSCT) should be considered, as recommended by the American Society of Hematology 1
Alternative options for refractory cases include anti-CD52 antibody (alemtuzumab) and JAK2 inhibitor (ruxolitinib), as suggested by the American College of Physicians 2

Mortality in adult HLH ranges from 20% to 88%, primarily due to refractory HLH, secondary infections, and progression of underlying disease, as reported by the American Society of Hematology 1
The prognosis for EBV-HLH has improved significantly with prompt treatment using HLH-94 protocols, as suggested by the American College of Physicians 1
Careful monitoring for secondary infections is essential, as they are a major cause of mortality in HLH patients, as recommended by the Infectious Diseases Society of America 3